News

Tue, 09/10/2018
High-ranking Lectures on Immunotherapy and its risks
Muenster. The Department of Neurology Muenster is pleased to announce its Neurology Seminar with guest lecturers Prof. Stephen Reddel and Prof. Helmut Butzkueven. Professor Stephen Reddel’s talk will focus on immunosuppression safety. Reddel is a staff specialist neurologist at Concord Repatriation & General Hospital Sydney, consultant neurologist at the Brain & Mind Centre, University of […]...more
Tue, 09/10/2018
Munich Cluster for Systems Neurology (SyNergy) will be funded
Munich. The Cluster for Systems Neurology (SyNergy) by LMU and TUM will receive funding from 2019 on. Currently SFB PIs Prof. Reinhard Hohlfeld, Prof. Martin Kerschensteiner, Prof. Mikael Simons are also PIs of SyNergy projects....more
Fri, 31/08/2018
Women in Science Network Conference “Decision Making in Infection and Immunity”
The female scientists invite you to the Women-in-Science Network Conference Münster 2018, co-funded by the SFB TR-128. This conference taking place on November 27 and 28 has two main goals: (1) to present and discuss top-level scientific contributions and (2) to increase visibility, encourage leadership, and provide a strong community for women in science. The […]...more


Wed, 23/11/2016 | Featured publication: Imaging matrix metalloproteinase activity in multiple sclerosis as a specific marker of leukocyte penetration of the blood-brain barrier

Münster – The enzymes gelatinase A/matrix metalloproteinase-2 (MMP-2) and gelatinase B/MMP-9 are essential for induction of neuroinflammatory symptoms in experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis (MS). In the absence of these enzymes, the disease does not develop. SFB128 scientists of Prof. Dr. Lydia Sorokin’s group, therefore, investigated the cellular sources and relative contributions of MMP-2 and MMP-9 to disease at early stages of EAE induction. They demonstrated that MMP-9 from an immune cell source is required in EAE for initial infiltration of leukocytes into the central nervous system and that MMP-9 activity is a reliable marker of leukocyte penetration of the blood-brain barrier.
The neuroscientists then developed a molecular imaging method to visualize MMP activity in the brain using fluorescent- and radioactive-labeled MMP inhibitors (MMPis).
By using radioactive MMP ligand in EAE animals the Muenster neuroscientists produced positron emission tomography (PET) images of MMP activity in patients with MS.
In contrast to traditional T1-gadolinium contrast-enhanced MRI, MMPi-PET enabled tracking of MMP activity as a unique feature of early lesions and ongoing leukocyte infiltration.
MMPi-PET therefore allows monitoring of the early steps of MS development and provides sensitive, noninvasive means of following lesion formation and resolution in murine EAE and human MS, the neuroscientists conclude. Their work was part of the SFB projects B03 and Z02.